#VisualAbstract: Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer
Click here to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Click here to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
1. Progression-free and overall survival was comparable in both the intervention and control groups. 2. Serious adverse events were more ...
Click here to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
1. The probability of progression-free survival at 12 months was 0.57 in the experimental group (cabozantinib plus nivolumab and ipilimumab) ...
1. Telaglenastat addition to cabozantinib did not show improvements in clinical benefit. 2. Adverse events of grades 3 or 4 ...
1. Objective response rate was 35%, with 1 patient showing a complete response and 7 showing a partial response. 2. ...
1. Intracranial response rate of 55% was reported in patients receiving cabozantinib with progressing brain metastases with no concomitant brain-directed ...
1. Progression-free survival was longer in patients in the cabozantinib group (9.0 months) than in the sunitinib group (5.6 months). ...
1. The combination of nivolumab and cabozantinib was superior to sunitinib in untreated advanced renal-cell carcinoma 2. The combination treatment ...
1. Progression-free survival was longer in patients in the cabozantinib group (9.0 months) than in the sunitinib group (5.6 months). ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.